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Abstract
Background: Great efforts have been made to increase accessibility of HIV antiretroviral therapy (ART) in low and middle-
income countries. The threat of wide-scale emergence of drug resistance could severely hamper ART scale-up efforts.
Population-based surveillance of transmitted HIV drug resistance ensures the use of appropriate first-line regimens to
maximize efficacy of ART programs where drug options are limited. However, traditional HIV genotyping is extremely
expensive, providing a cost barrier to wide-scale and frequent HIV drug resistance surveillance.
Methods/Results: We have developed a low-cost laboratory-scale next-generation sequencing-based genotyping method
to monitor drug resistance. We designed primers specifically to amplify protease and reverse transcriptase from Brazilian
HIV subtypes and developed a multiplexing scheme using multiplex identifier tags to minimize cost while providing more
robust data than traditional genotyping techniques. Using this approach, we characterized drug resistance from plasma in
81 HIV infected individuals collected in Sa ˜o Paulo, Brazil. We describe the complexities of analyzing next-generation
sequencing data and present a simplified open-source workflow to analyze drug resistance data. From this data, we
identified drug resistance mutations in 20% of treatment naı ¨ve individuals in our cohort, which is similar to frequencies
identified using traditional genotyping in Brazilian patient samples.
Conclusion: The developed ultra-wide sequencing approach described here allows multiplexing of at least 48 patient
samples per sequencing run, 4 times more than the current genotyping method. This method is also 4-fold more sensitive
(5% minimal detection frequency vs. 20%) at a cost 3–56less than the traditional Sanger-based genotyping method. Lastly,
by using a benchtop next-generation sequencer (Roche/454 GS Junior), this approach can be more easily implemented in
low-resource settings. This data provides proof-of-concept that next-generation HIV drug resistance genotyping is a feasible
and low-cost alternative to current genotyping methods and may be particularly beneficial for in-country surveillance of
transmitted drug resistance.
Citation: Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, et al. (2012) Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for
Surveillance of HIV Drug Resistance. PLoS ONE 7(5): e36494. doi:10.1371/journal.pone.0036494
Editor: Jason D. Barbour, University of Hawaii Manoa, United States of America
Received March 27, 2012; Accepted April 3, 2012; Published May 4, 2012
Copyright:  2012 Dudley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work at UW-Madison was supported by a National Institutes of Health R01 grant Al077376. The study was also supported by grants 2004/15856-9 and
2006/50096-0 from the Fundac ¸a ˜o de Amparo a Pesquisa do Estado de Sao ˜ Paulo (FAPESP). SS and MMS have been supported by CAPES scholarships; LFT and PRC
have been supported by FAPESP scholarships. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: doconnor@primate.wisc.edu
Introduction
Availability of antiretroviral therapy (ART) is increasing in low
and middle-income countries [1]. There is mounting evidence
suggesting that transmitted drug resistance increases over time as
ART use increases [2–4]. For example, in Kampala, Uganda, a
massive scale-up of ART was initiated in the year 2000 and a small
survey performed in 2006–2007 suggested no detection of
transmitted drug resistance [2]. Another survey performed in
Kampala between 2009 and 2010 showed a prevalence of
transmitted drug resistance at 8.6%, suggesting that while this
resistance may not immediately arise after scale-up, over time it
increases in prevalence. Transmitted drug resistance may thwart
current efforts to scale-up treatment in low and middle-income
settings where few treatment options are available. It is highly
recommended by the World Health Organization (WHO) that
surveillance of drug resistance occur in conjunction with scale-up
efforts to ensure appropriate first-line therapy is offered relative to
the resistance that exists [5]. It is believed that surveillance will
maximize the utility of first-line therapy and help minimize the
cost of providing ART thereby sustaining current antiretroviral
drug programs. This is particularly important as treatment
guidelines now recommend earlier start of ART, prolonging the
period of time individuals are taking antiretroviral drugs, and
increasing the opportunity for drug resistance to develop and
transmit [6]. However, drug resistance surveillance remains highly
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settings.
We have developed a method using the next-generation Roche/
454 sequencing platform to monitor HIV drug resistance through
genotyping. By coupling multiplexing together with a lower-cost
laboratory-scale next-generation sequencer (Roche/454 GS Ju-
nior), we reduce the cost of drug resistance surveillance by 3–5-fold
allowing its implementation in resource-limited settings. In
addition, because next-generation sequencing is clonal in nature,
it provides increased sensitivity over traditional Sanger-based
sequencing that will enable future work to understand the
dynamics of the emergence of drug resistance within a population.
We refer to our approach as ‘‘ultra-wide’’ drug resistance testing
because the large number of sequence reads obtained in a single
Roche/454 pyrosequencing run can be applied across at least 48
different patient samples. This is different than the more
traditional application of sequencing a single patient sample to
study HIV in an ‘‘ultra-deep’’ manner. 48 samples is also four
times larger than the number of samples that can be simulta-
neously sequenced using traditional Sanger-based HIV drug
resistance genotyping.
Here we present a proof-of-principle study using our Roche/
454 pyrosequencing approach to study drug resistance in a cohort
of HIV-positive individuals enrolled in a study through the
University of Sa ˜o Paulo in Brazil. We obtained samples from 81
HIV-infected individuals either exposed or not exposed to
antiretroviral therapy. We designed primers to amplify protease
and the first 735 nucleotides of reverse transcriptase to encompass
mutations identified through the Stanford HIV drug resistance
database and the WHO drug resistance surveillance list. We
optimized PCR strategies to amplify HIV from Brazil (primarily
subtype B) with a range of viral loads. After multiplexing up to 48
patient samples/sequencing run and analyzing the data through
an open-source in-house analysis pipeline, we identified drug
resistance mutations in 13/70 (18.5%) of samples in our cohort.
When considering only the treatment-naı ¨ve samples, 10/50 (20%)
of HIV+ individuals harbored one or more drug resistance
mutations. Altogether, we show the feasibility of multiplexing 48
patient samples together in a single Roche/454 GS Junior
pyrosequencing run to obtain high quality and sensitive HIV
drug resistance genotyping information. Through this multiplexing
approach, the sequencing cost is reduced to USD $20/sample,
which is 3–56 less expensive than traditional Sanger-based
sequencing methods performed as part of either in-house or
commercial kits. This approach is adaptable to different HIV
subtypes and can be scaled up to accommodate larger surveillance
efforts.
Methods
Ethics Statement
The subjects used in this study provided informed written
consent. The protocol and consent form for phlebotomy were
approved by the ethics committees at the University of Sa ˜o Paulo
(USP) and the Federal University of Sa ˜o Paulo. The collected
samples were de-identified and sent to the University of
Wisconsin-Madison for sequencing and met the criteria for IRB
exemption from the University of Wisconsin health sciences
minimal risk IRB, protocol M-2008-1167.
Study Subjects
Eighty-one patient samples were selected to include in this study
from the Serologic Testing Algorithm for Recent HIV Serocon-
version (STAHRS) cohort [7]. This cohort, mostly constituted by
men who have sex with men recently infected by Clade B strains,
continues to collect samples over time for multiple years [8]. 55
samples were collected between 1998 and 2003 from patients prior
to antiretroviral treatment (ART). The mean viral load of these
samples was 100,547 copies/ml with a standard deviation of
129,646 copies/ml. 12 samples were selected from individuals
following ART and with no drug failure as measured by
undetectable viral loads. The limit of detection of the viral load
assay using the Amplicor HIV-1 Monitor test was 400 copies/ml
for samples processed before January, 2007, and 50 copies/ml
after this date using the Versant HIV-1 RNA 3.0 assay using
branched DNA. Lastly, 14 samples were chosen from individuals
failing ART, defined as having detectable viral loads, with mean
viral loads of 10,221 copies/ml and a standard deviation of 20,519
copies/ml. Most patients on ART received a standard first-line
therapy regimen including efavirenz (non-nucleoside reverse
transcriptase inhibitor (NNRTI)), lamivudine (nucleoside reverse
transcriptase inhibitor (NRTI)), and zidovudine (NRTI). Two
patients (patient ID 2008 and 1015) were taking a combination of
zidovudine, lamivudine, lopinavir, and ritonavir and one patient
(patient ID 2039) was taking a combination of zidovudine,
lamivudine, and atazanavir boosted with ritonavir at the time of
post-treatment sample collection. Samples collected after the start
of antiretroviral therapy were collected between 2003 and 2007.
Sample Preparation and PCR Amplification
A schematic representing the major steps to prepare samples for
drug resistance genotyping using the method described in this
paper is presented in Figure 1. Plasma from each sample was
centrifuged at 14,0006rpm at 4uC for 1 hour to concentrate virus
for viral RNA extraction using the QIAamp Viral RNA Mini Kit
(Qiagen). Viral RNA was subjected to one-step RT-PCR
amplification using Superscript III Reverse Transcriptase and
High Fidelity Platinum Taq Polymerase (Invitrogen). We designed
three primer sets that were used to amplify the entire protease
gene (Pro) and the first 735 nt of the reverse transcriptase gene in
two halves (RT1 and RT2). Fusion primers containing the Roche
454 titanium amplicon adaptor sequences, multiplex identifier
(MID) tags on both forward and reverse primers, and the
sequence-specific primer were generated (Integrated DNA tech-
nologies). The sequence-specific portions of the primers are as
follows: Protease (Pro) forward 59- AACTCCCTCTCMGAAG-
CAGGAG-39 and reverse 59- CTGGCTTTAATTT-
TACTGGTA-39; reverse transcriptase 1 (RT1) forward 59-
AAATTAAAGCCAGGAATGGA-39 and reverse 59-
TGTCTCAATGTTTGTACTAGGTAT-39; and reverse tran-
scriptase 2 (RT2) forward 59-TGGGTGATGCATATTTTT-
CAG-39 and reverse 59-GCACTATAGGCTGTACTGTCC-39.
The full sequences containing MID tags and adaptors for the 48
primer sets used to amplify the samples in this project are
presented in Table S1. PCR conditions were as follows: 50uC for
60 min. for reverse transcription; 94uC for 2 min. to activate
polymerase; 2 cycles of 94uC for 15 sec., 60uC for 30 sec., and
68uC for 30 sec.; 2 cycles of 94uC for 15 sec., 58uC for 30 sec.,
and 68uC for 30 sec; 36 cycles of 94uC for 15 sec., 55uC for
30 sec., and 68uC for 30 sec.; and lastly a final 10 min. extension
was performed at 68uC.
Samples that did not amplify during a single round of PCR were
subjected to nested PCR, but were amplified in a total of 40 cycles
between both external and nested PCR amplifications. Viral RNA
was amplified using the one-step RT-PCR approach as described
above with the following external primer pairs: Protease forward
59-AGCTTCAGGTTTGGGGARGAG-39 and reverse 59-
TGTTTAACTTTTGGGCCATCC-39; RT1 forward 59-
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CTGTGGAAGCACATTGTACTG-39; RT2 forward 59-GAA-
TACCACATCCCGCAGG-39 and reverse 59-ACTTGCC-
CAATTCAATTTTCC-39. The PCR conditions were as follows:
50uC for 60 min. for reverse transcription; 94uC for 2 min. for taq
activation; 2 cycles of 94uC for 15 sec., 60uC for 30 sec., and 68uC
for 30 sec.; 2 cycles of 94uC for 15 sec., 58uC for 30 sec., and
68uC for 30 sec; 16 cycles of 94uC for 15 sec., 55uC for 30 sec.,
and 68uC for 30 sec.; and lastly a final 10 min. extension was
performed at 68uC. 15 ml of the 25 ml RT-PCR product was
subjected to nested PCR amplification using the same cycling
conditions as the external PCR reaction minus the 50uC reverse
transcription step, and using the same fusion primer sets described
for the single round amplifications above containing Roche 454
adaptors and MID tags.
Sample Quantitation and Purification
Following PCR amplification, samples with higher viral loads
(.2,000 copies/ml) were subjected to agarose gel electrophoresis
and gel purified using a MinElute Gel Extraction Kit (Qiagen)
(Figure 1). Samples from individuals with low or undetectable viral
load were analyzed on an Agilent Bioanalyzer 2100 high sensitivity
DNA chip to verify product size and purity. All PCR samples were
purified using an AMPure XP (Agencourt) bead clean-up at a
bead:DNA volume ratio of 0.8:1. Samples were then quantitated
using picogreen dye and the Qubit (Invitrogen) fluorometer. PCR
products were pooled together at equimolar ratios to prepare for
Roche/454 pyrosequencing. A final AMPure bead clean-up was
performed on the pooled samples and a final Qubit quantitation of
the pool was taken to calculate correct copy numbers for emulsion
PCR. Finally, the DNA pool was analyzed on the Agilent
Bioanalzyer 2100 to ensure removal of all primer/primer-dimer
short products by the AMPure bead clean-up before emulsion
PCR.
Ultra-wide Pyrosequencing
All samples were sequenced as part of two independent Roche/
454 GS Junior runs. Emulsion PCR was performed according to
Roche/454 manufacturer instructions. The sample libraries were
added to the emulsion PCR at a ratio of two molecules per bead.
Following the enrichment of the emulsion PCR products, the
picotiter plate (PTP) was prepared and 500,000 enriched beads
were loaded per the instruction manual provided by Roche/454.
Data Analysis
Sequence files in a Standard Flowgram Format (SFF) generated
following the sequencing runs were analyzed using a custom
analysis pipeline. This pipeline utilized Samtools and BioPerl
[9,10]. This pipeline has been made available as a module for
LabKey Server, an open-source platform for the management of
scientific data (www.labkey.com). The LabKey Sequence Analysis
module provides a web-based interface to initiate analyses,
Figure 1. Schematic representation of the sample preparation for ultra-wide HIV drug resistance genotyping using Roche/454
pyrosequencing. A.) Plasma is isolated from 48 patient samples using centrifugation. B.) Viral RNA is extracted from ,1 ml of plasma from each
sample. C.) One-step RT-PCR is used to reverse-transcribe and PCR-amplify 3 amplicons spanning the HIV pol gene from each sample as shown. Each
sample is amplified with primers containing a unique multiplex identifier (MID) tag (1–48). D.) PCR products are gel purified and purified further using
size exclusion magnetic beads. E.) Purified samples are quantitated and pooled together at equimolar ratios for a total of 144 amplicons/pool. F.) Each
pool is subjected to emPCR followed by pyrosequencing on the Roche/454 GS Junior.
doi:10.1371/journal.pone.0036494.g001
Ultra-Wide HIV Drug Resistance Genotyping
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36494manage data, and view results. The source code behind this
pipeline is available in a subversion repository (https://hedgehog.
fhcrc.org/tor/stedi/trunk/server/customModules/
SequenceAnalysis). The pipeline performs three steps: pre-
processing of sequence, alignment, and SNP calling. The raw
sequence data was processed as follows: sequences were converted
to FASTQ format, separated by MID tag, trimmed on the 39 end
based on quality scores (using a sliding window of 10 nt, requiring
an average quality score of at least 17 in this window), the Roche/
454 amplicon adaptors were trimmed (adaptor A: 59
CGTATCGCCTCCCTCGCGCCATCAG 39; adaptor B:
59CTATGCGCCTTGCCAGCCCGCTCAG 39), and reads less
than 200 bp were discarded. Next, the sequences were aligned to
the HXB2 reference strain (GenBank NC_001802) using BWA-
SW to create a BAM alignment [11]. All bases of the alignment
were evaluated and single nucleotide polymorphisms (SNPs) were
called for bases with a quality score above 19 and deletion/
insertion polymorphisms were called for bases with a quality score
above 25. Importantly, the identity of the associated read was
retained for each SNP, which allows the phase of SNPs to be
considered. This information allowed amino acid translations to be
calculated based on the sequence of each individual read, as
opposed to the consensus sequence. The information produced
during the analysis process was stored in the LabKey database,
from which results were viewed and reports generated. The
analysis pipeline reduced the sequence data to lists of SNPs relative
to the reference strain that were viewed in both nucleotide and
amino acid format. To simplify drug resistance analysis further,
one of the reports generated by this pipeline presents a list of the
specific amino acid changes that correspond to sites of known drug
resistance mutations based on the Stanford HIV drug resistance
data base (Stanford HIVDB) matrices. Frequencies of each
mutation found in our patient samples as well as the number of
sequences representing that amino acid site, adjusted for only high
quality sequences, were taken from this drug resistance report.
Sequence data including the alignment file (.bam) and translated
SNPs (.txt) from this analysis is available at https://ehr.primate.
wisc.edu/project/WNPRC/WNPRC_Laboratories/oconnor/
public/begin.view?. Lastly, sequences were also visualized using
Geneious software (version 5.5.6) to confirm the mutations
identified by the analysis pipeline as well as to assess which
amplicons contained sequence information. The SFF files
containing the sequencing results from the Roche/454 GS Junior
were uploaded into Geneious and assembled to the HXB2
reference sequence previously described.
HIV Plasmid and Clonal HIV Stock Sequencing
To assess the error associated with reverse transcription, PCR
amplification and Roche/454 pyrosequencing, we sequenced both
an HXB2 HIV plasmid (pHXBn-PLAP-IRES-N+ was obtained
through the NIH AIDS research and reference reagent program,
Division of AIDS, NIAID, NIH from Dr. Benjamin K. Chen and
Dr. David Baltimore) and clonal viral stock. To produce the clonal
viral stock, the pHXBnPLAP-IRES-N+ (HXBn) plasmid was
transfected into 239T packaging cells using the Xfect Transfection
Reagent (Clontech). The supernatant was collected two days after
transfection to limit virus production to a single round and the
virus was quantitated using the Lenti-X qRT-PCR titration kit
(Clontech). Viral RNA was isolated from this supernatant (viral
load=115,000 copies/ml) and subjected to one-step RT-PCR and
sequenced using the same protocol that was used to sequence
patient samples. Both DNA and viral RNA starting templates are
expected to have no SNPs relative to the HXB2 reference
sequence (GenBank NC_001802). The plasmid DNA was
sequenced using the same protocol as the patient samples without
the initial reverse transcription step. In addition, we sequenced the
HIV plasmid using a Sanger-based approach as a standard to
verify the sequence of the plasmid in the pol gene. This verification
revealed two mutations in the pol gene (HXB2 positions 1805 and
2473) of the plasmid that were not expected based on the
published map of the vector. These mutations in the plasmid were
ignored during analysis. All other SNPs found by pyrosequencing
in either the plasmid or the viral stock were considered ‘‘false
SNPs’’ that likely resulted from error in the PCR, pyrosequencing,
or analysis of the sequences. SNPs with frequencies above the
‘‘false SNPs’’ were considered real changes that do not likely stem
from error associated with the sequencing method, from which we
established the minimum frequency threshold used in our
sequence analysis of patient samples (described below).
Results
Determining Error Threshold of the HIV Drug Resistance
Genotyping Method
To assess the error associated with our sample preparation,
sequencing, and analysis methods, we processed and pryose-
quenced a HXB2 HIV plasmid and a clonal HIV viral stock not
expected to have any mutations relative to the HXB2 reference
sequence (GenBank NC_001802), as described in the materials
and methods. The average depth of sequence coverage per
nucleotide position for the clonal virus stock was 826 (+/2212)
sequences (Figure 2). As a comparison, the HXBn plasmid was
sequenced using the same methods without the reverse transcrip-
tion step. The plasmid was sequenced from two independent PCR
amplifications in one sequence run and was differentiated by a
multiplex identifier tag. The average depth of sequence coverage
for each MID tag was 826 (+/2223) and 1009 (+/2348)
sequences (Figure 2). This sequence coverage is similar to the
coverage obtained when sequencing our patient samples (Figure 3).
Analysis of the pyrosequencing results from both the plasmid
and viral stock starting material showed no ‘‘false’’ drug resistance
mutations above a frequency of 0.71% and in no more than 4
sequence reads (Table 1). Based on this data, we chose a
Figure 2. Sequence coverage of three amplicons from a clonal
HXB2 viral stock and HXB2 plasmid. The number of sequences
from the clonal viral stock (red) or HIV plasmid (blue and black) that
aligned to each nucleotide position of the NC_001802 HXB2 HIV
reference sequence is shown across the pol gene. The HXB2 vRNA
clonal viral stock was sequenced under one GS Junior sequencing run,
while two independent PCR amplifications were used to sequence the
plasmid under two different MID tags in a separate GS Junior
sequencing run. Pyrosequencing was performed on three overlapping
amplicons with nucleotide positions for each amplicon represented at
the top of the graph.
doi:10.1371/journal.pone.0036494.g002
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samples for drug resistance mutations, ,7-fold above our
predicted error rate. Assessment of the error associated with our
sequencing method outside of the drug resistance sites or in
changes that don’t create specific drug resistance mutations is
provided in Text S1 and Table S2.
Sequencing Statistics from Patient Samples
Patient samples were sequenced in two independent Roche/454
GS Junior runs (Table 2). After trimming low quality sequences off
the ends of the sample reads, the average sequence length that
aligned to the reference sequence for each run was 374 bp and
363 bp for runs 1 and 2 respectively. These sizes are slightly
smaller than the total amplicon sizes that range from 386 bp–
404 bp, indicating near full-length coverage of each sequence from
both read directions. The average coverage varied with each
sequencing run as well as at each nucleotide site associated with
drug resistance mutations. Figure 3 shows coverage of sequences
that aligned to HXB2 before (coverage) and after (adjusted
coverage) low quality sequences were removed from a few
representative samples from the first GS Junior run. In general,
coverage spikes correspond to regions of overlap between the
primer sets as shown at the top of Figure 3. Coverage dips, which
are consistent between samples, typically fall at the ends of
homopolymer regions where the sequence quality scores drop due
to pyrosequencing chemistry. Adjusted coverage is reported for
SNPs found in both the control and patient samples and was used
to determine the frequencies reported in Tables 1, 3, and S2.
Success Rate of the PCR Amplification and Sequencing
Method
We obtained 81 samples from HIV+ individuals with varying
viral loads that ranged from undetectable-506,000 copies/ml.
Altogether, we amplified all three amplicons from 58/81 (72%) of
the samples we received. Using the viral load threshold of 1,000
copies/ml, which is typically used by HIV drug resistance
genotyping methods developed in-house (2,000 copies/ml for
FDA approved genotyping kits), we amplified 54/59 (92%)
samples (viral load range=3,280–506,000 copies/ml). Of the 5
samples above the 1,000 copies/ml viral load threshold that did
not amplify all three amplicons, 1 failed to amplify the protease
amplicon, 2 failed to amplify the RT1 amplicon, 1 failed to
amplify the protease and RT2 amplicons, and 1 failed to amplify
all three amplicons. Of the samples with PCR amplicons, 178/191
(93%) of the amplicons yielded high quality sequence data. Six
protease amplicons failed to sequence, 5 RT1 amplicons failed to
sequence and 2 RT2 amplicons failed to sequence. 6/13 of the
failed amplicons had concentrations less than 2 ng/ul after PCR
amplification and purification.
Characterization of HIV Subtype
The sequences obtained were assembled to the HXB2 reference
sequence (GenBank NC_001802) using Geneious software. A
consensus sequence for each sample was exported and analyzed
for subtype using the Stanford drug resistance database (http://
hivdb.stanford.edu/) and the NCBI HIV subtyping tools (http://
www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi). Sub-
typing was confirmed through the Rega version 2.0 subtyping
tool (http://dbpartners.stanford.edu/RegaSubtyping/). We found
one subtype F sample, two subtype C samples, one subtype B/C
recombinant, three subtype B/F recombinants and the remaining
samples were subtype B. The pure subtype F sample, three B/F
recombinant samples and the B/C recombinant sample amplified
and sequenced all three amplicons. One sample with subtype C
sequence failed to amplify the protease and RT2 amplicon, while
the other subtype C sample failed to sequence the protease
amplicon.
Characterization of HIV Drug Resistance Mutations
The data (.sff file) generated at the end of the Roche/454 GS
Junior run were imported into the viral sequence analysis pipeline
using the parameters described in the materials and methods.
Mutations were characterized as drug resistant if they matched the
list of major drug resistance mutations in the Stanford HIVDB
resistance matrices. For the purposes of this analysis, additional,
accessory, and polymorphic mutations were not considered except
for mutations found at position V179. These additional mutations
typically play a more minor role in acquisition of drug resistance
and are also not included in the WHO list of mutations to survey
for transmitted drug resistance. Mutations at the V179 site in
reverse transcriptase were part of the major drug resistance matrix
until January 25, 2012, when they were reclassified as minor
mutations. However, V179 mutations were found in 4/7
individuals eventually failing their drug regimen in our cohort.
Overall, drug resistance mutations were identified in 13/70
(18.5%) of patient samples with sequence information (Table 3).
20% (10/50) of drug naı ¨ve samples harbored drug resistance
mutations (without considering V179 mutations, the frequency of
mutations in drug naı ¨ve samples is 12% (6/50)). 60% (3/5) of
treatment failure samples with viral loads .1,000 copies/ml and
with full sequence coverage exhibited drug resistance, while 17%
(1/6) of treatment success patients with partial or complete
sequence coverage (all with undetectable viral loads) harbored
drug resistance mutations. Overall, 50% (6/12) of individuals
failing treatment with some or full sequence coverage irrespective
of viral load exhibited drug resistance mutations before and/or
after treatment. The number of individuals on treatment that were
sequenced in this study is very small and therefore frequencies of
drug resistance presented here in treatment failures are not
generalizable to the population in Brazil.
The two most common drug resistance mutations found prior to
treatment were V179D/E and K103N. These mutations are
associated with resistance to efavirenz, a NNRTI component of
first-line regimens in Brazil. All patients exhibiting V179
Figure 3. Sequence coverage and adjusted sequence coverage
of three representative patient samples. The number of
sequences representing each nucleotide position (coverage) from three
patient samples sequenced in the same GS Junior run is shown after
alignment to the NC_001802 HXB2 HIV reference sequence. Also shown
is the number of sequences that align to each nucleotide position after
eliminating sequences with low quality scores (adjusted coverage) at
each nucleotide position for each patient sample. Pyrosequencing was
performed on three overlapping amplicons with nucleotide positions
for each amplicon represented at the top of the graph.
doi:10.1371/journal.pone.0036494.g003
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treatment. Conversely, K103N mutations found prior to treatment
never resulted in drug failure, but were found in three individuals
after failing treatment. Overall, prior to treatment, eight patients
had resistance to NNRTIs only, one patient had resistance a
protease inhibitor (PI) only, and one patient showed resistance to a
PI + NRTI (Table 3). Three of the drug naive patients with drug
resistance mutations (patient IDs 1083, 1053, and 2032) were
sequenced from samples at the time of diagnosis (visit 1). These
mutations may therefore exemplify transmitted drug resistance.
The remaining six treatment naı ¨ve patients with drug resistance
mutations were sampled at different time points after diagnosis
that ranged from visit 2 to visit 9 and therefore there is less
certainty about whether these mutations were transmitted or a
result of spontaneous mutation. 53% (7/13) of the samples
harboring drug resistance mutations either before or after
treatment, failed their treatment regimen.
Discussion
We have described a method to multiplex together 48 patient
samples to simultaneously test for HIV drug resistance using
Roche/454 pyrosequencing on the GS Junior. We tested this
method on 81 patient samples collected in Sa ˜o Paulo, Brazil. Most
notably, we identified mutations associated with drug resistance in
20% of treatment naı ¨ve patients in our cohort. Importantly, the
most frequent drug resistance mutations identified (K103N and
V179D/E) correlate with drug resistance to efavirenz, a
commonly used drug in first-line therapy in Brazil and many
other countries. In addition, K103N, V179D/E, and other
NNRTI mutations have a low genetic barrier whereby a single
mutation can render resistance. This finding emphasizes the
importance of surveying for transmitted HIV drug resistance and
highlights the significance of developing tools such as those
provided here to perform these surveys faster and cheaper to
choose optimal first-line therapies.
The results presented here are similar to those previously
reported, showing a frequency range of 6.5%–26.9% for
treatment-naı ¨ve individuals from Brazil harboring HIV drug
resistance mutations [8,12–14]. Sanabani et al. reported a 13.7%
frequency (n=101) of primary drug resistance based on the WHO
list of mutations for surveillance of transmitted drug resistance
Table 1. ‘‘False’’ drug resistance mutations found in the HXB2 plasmid or HXB2 viral stock.
HXB2 source
1 Resistance mutation Drug class Frequency (%) Adjusted coverage Total reads with mutation
Plasmid 2 M41L NRTI 0.10 1010.0 1.0
Plasmid 1 K70R NRTI 0.43 700.0 3.0
Plasmid 1 V106A NNRTI 0.15 686.0 1.0
Plasmid 1 Y181C NNRTI 0.11 902.0 1.0
Plasmid 1 M184I/V NRTI 0.33 902.0 3.0
Plasmid 2 M184I NRTI 0.18 560.0 1.0
Plasmid 1 Y188H NNRTI 0.22 896.0 2.0
Plasmid 1 M230L NNRTI 0.14 705 1.0
Plasmid 1 V32I Protease 0.13 765.0 1.0
Plasmid 1 M46I/L Protease 0.71 421.0 3.0
Plasmid 2 M46L Protease 0.14 707.0 1.0
Virus I47V Protease 0.29 695.0 2.0
Plasmid 2 I47V Protease 0.09 1123.0 2.0
Plasmid 1 I47V Protease 0.14 721.0 1.0
Plasmid 2 I50V Protease 0.27 1098.0 3.0
Plasmid 2 I54T/V Protease 0.40 994.0 4.0
Virus I54V Protease 0.16 643.0 1.0
Plasmid 2 L76V Protease 0.08 1185.0 1.0
Plasmid 2 V82A Protease 0.17 1203.0 2.0
Virus V82A Protease 0.27 736.0 2.0
Plasmid 1 V82A Protease 0.13 763.0 1.0
Plasmid 1 N88D Protease 0.28 717.0 2.0
Plasmid 2 N88D/S Protease 0.35 1142.0 4.0
1Plasmid 1 and 2 refer to data from two independent experiments used to sequence the same HXBn plasmid. Virus refers to the data from sequencing a viral stock
derived from the HXBn plasmid.
doi:10.1371/journal.pone.0036494.t001
Table 2. The statistics of the two GS Junior runs used to
assess the patient samples in this study.
GS Junior run #1GS Junior run #2
# of amplicons 123 75
# of patients 48 39
# sequence reads 77,071 118,295
# sequences/MID 1,602+/21,260 3,024+/22,203
doi:10.1371/journal.pone.0036494.t002
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traditional Sanger-based genotyping of proviral DNA [8].
Similarly, we found that 12% of drug naı ¨ve individuals from the
same cohort harbored drug resistance mutations when considering
only the WHO list of mutations (this excludes V179D and V179E
mutations). Therefore, our sequencing method yielded similar
Table 3. Drug resistance mutations identified in the patient samples sequenced using the Roche/454 GS Junior HIV drug
resistance genotyping method.
Sample ID Time relative to ART Resistance mutation Drug class Frequency (%) Adjusted coverage Failed Rx?
1001 Before K103N NNRTI 98.4 62
After N/A No
1083 Before G190A NNRTI 99.5 2019
Y181C NNRTI 99.5 1913
After N/A (Died) Yes
1053 Before K103N NNRTI 100.0 179
After N/A No
2018 Before K103N NNRTI 99.6 253
E138G NNRTI 45.8 1348
After N/A No
2015 Before M46I PI 4.7 300
After N/A No
1050 Before M46I PI 98.1 107
I54V PI 100.0 204
V82S PI 100.0 205
L210W NRTI 98.3 2290
T215Y NRTI 84.3 1612
M41L NRTI 99.3 150
D67N NRTI 24.1 83
After M46I PI 99.2 515 No
I54V PI 99.6 1146
V82S PI 99.8 1150
L210W NRTI 99.6 978
T215Y NRTI 78.0 615
M41L NRTI 98.0 49
K65R NRTI 11.1 9
D67N NRTI 13.5 37
1128 Before K103N NNRTI 23.4 124
After N/A N/A
2031 Before V179E NNRTI 99.8 988
After M184V NRTI 99.7 641 Yes
V179E NNRTI 99.3 587
K103N NNRTI 85.7 42
1080 Before V179D NNRTI 17.7 767
After V179D NNRTI 99.5 375 Yes
1094 Before None
After V179D NNRTI 11.8 722 Yes
K103N NNRTI 13.9 36
2032 Before V179E NNRTI 99.2 499
After N/A Yes
1004 Before None
After K103N NNRTI 77.2 22 Yes
1033 Before None
After V106M NNRTI 6.5 170 Yes
doi:10.1371/journal.pone.0036494.t003
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performed on the same Brazilian cohort.
It should also be noted that there were 33 treatment-naı ¨ve
patient samples used in our cohort that were previously genotyped
for drug resistance using Sanger-based methods on proviral DNA
[8]. Many of these previously published patient samples were from
the first time point of diagnosis while those in our cohort were
often from time points beyond the first visit. There was
concordance of drug resistance mutations between the two studies
with two exceptions. The first exception was one sample (patient
ID 2018) where Sanabani et al. found a M184V mutation at visit 1
that was detected in only 1 sequence by pyrosequencing in the visit
5 sample we pyrosequenced. It is likely that during the time
between visit 1 and 5 this mutation waned due to the absence of
selection pressure by antiretroviral drugs. The second exception
was patient ID 2015 where our method picked up a M46I protease
mutation at a frequency of 4.7%, well under the frequency
limitation of Sanger-based methods. Patient 2015 was the only
sample with low frequency mutations found by our method before
treatment that was also sequenced by the Sanabani et al., but
suggests that our method will detect mutations at a lower
frequency than the Sanger-based genotyping methods.
It is clear that viral load significantly impacted PCR amplifi-
cation of samples in our cohort. By designating a minimum viral
load of 1,000 copies/ml, we improved the frequency of successful
amplification of all three amplicons from 72% to 92%. It is
possible that some samples that failed to amplify are from non-B
subtypes or recombinants, which requires additional optimization
of PCR primers. Many samples with viral loads .1,000 copies/ml
that did not amplify all three regions of Pol did amplify 1 or 2
regions. This inability to amplify all three amplicons likely stems
from mismatches between the PCR primers and the HIV
template, which can occur between different viruses in the same
subtype. As sequencing technology advances and read lengths
continue to improve, it may become feasible to generate and
sequence a single amplicon spanning the entire drug resistance
region in Pol (,1,000 nt) that would further improve the efficiency
of this method. The current Roche/454 titanium chemistry is
limited to sequence lengths of about 450 bp. This chemistry will be
the only available chemistry on the laboratory-scale Roche/454
GS Junior, however, longer read lengths may be feasible with
advanced Roche/454 chemistries being developed on their full-
size Roche/454 GS FLX pyrosequencer. As exemplified by the
99% success rate of initial amplification seen with a single primer
pair in the FDA approved ViroSeq Sanger-based drug resistance
genotyping assay, the fewer primers required to amplify HIV, the
less likely mismatches between the primer and template result in
inability to PCR amplify HIV [15]. The larger concern with the
ViroSeq method occurs downstream during sequencing when
seven primer pairs are required to match the HIV template for the
sequencing reactions.
The .1,000 copies/ml viral load requirement designated for
this method is the same as the those required for the ViroSeq
genotyping kit as well as in-house genotyping options, ranging
from 1,000–2,000 copies/ml. In addition, WHO standards to
survey for emergent drug resistance mutations suggest HIV drug
resistance genotyping be performed only on samples with viral
loads over 1,000 copies/ml [16]. Since most samples tested for
HIV drug resistance would either include individuals not yet on
treatment for surveillance of transmitted drug resistance, or
individuals failing treatment, a viral load threshold of 1,000
copies/ml is reasonable.
It is difficult to compare the results from Roche/454
pyrosequencing to methods currently using Sanger-based ap-
proaches because they use completely different sequencing
chemistries. One published assessment of the ViroSeq assay
showed that while 99% of their initial PCR amplifications were
successful, success of full bidirectional sequencing using each of
their seven primers varied from 56% to 100% in samples from
different subtypes [15]. This range in successful sequencing is likely
due to possible mismatches between the seven sequencing primers
and the HIV template. This problem is eliminated in pyrose-
quencing because the sequencing primer binds to an adaptor
sequence that is engineered into the PCR primers used to prepare
each sample for sequencing.
The ViroSeq assay was specifically designed to test HIV subtype
B samples and indeed these samples yielded the highest success
rate for the ViroSeq assay. In one study, 6/7 of the primers
sequenced the subtype B template in 100% of the 12 samples
tested and 1/7 primers sequenced 83% (10/12) of subtype B
samples [15]. However, for subtypes F and C, 78% and 69% of
samples yielded bidirectional sequence coverage using Viroseq. In
our assay, also designed specifically around subtype B, we obtained
high quality sequences from 93% of the amplicons included in our
sequencing pools. Our samples were primarily subtype B, but also
included a few subtype F and C samples as well as recombinants.
The overall efficacy of this method for non-B subtypes has not
been thoroughly tested yet, however, we have redesigned some of
the primers based on subtype C sequence and have been able to
amplify subtype C reference viruses with these primer sets.
Reasons for sequence failure in pyrosequencing are not due to
primer mismatch with template, like in Sanger sequencing, but
may be related to issues during the pooling process. This is further
supported by the fact that there is no pattern of a particular
amplicon sequencing less often than another, suggesting that it is
not a sequence-specific problem. Instead, low concentrations of
the amplicon DNA after purification may lead to less reliable
quantitation and pooling or poor amplification of a specific
product during emPCR. Some of the sample pooling done in this
study was performed by an automated liquid handler, therefore it
is possible that some samples were unintentionally left out of the
pool if their volumes were at the minimum required for the robot
and no volume was picked up out of those wells and added to the
pool. Given the chemistry of pyrosequencing, there are few
reasons for sequencing failures once a high quality amplicon is
produced during the initial PCR amplification and after proper
purification of that PCR product. More robust pooling options as
well as setting a threshold for minimal concentration of a PCR
purified product required for this assay may improve our 93%
success rate of sequencing those amplicons included in our pool.
One of the main advantages of ultra-wide drug resistance
genotyping is the economy of scale savings associated with dividing
a sequencing run between 48 samples. While the cost of preparing
the samples for sequencing is comparable between in-house
genotyping, commercial-based kits like TruGene or Viroseq, and
454 pyrosequencing, the cost of sequencing alone is about 3–5
times less per sample for Roche/454 GS Junior sequencing over
traditional Sanger-based sequencing. A Roche/454 GS Junior run
costs about $1000 or ,$20 per sample when 48 samples are
multiplexed together. This is even less than previous publications
utilizing the full-size Roche/454 GS FLX sequencer for drug
resistance surveillance, which costs approximately $57/sample
when 48 samples are run in two 1/16 lanes [17]. Therefore, it is
possible to leverage the tremendous savings of pyrosequencing and
scale of this method to improve feasibility of drug resistance
surveillance. In addition, our pyrosequencing method can
sequence 48 patient samples at one time yielding hundreds of
sequences per sample while traditional HIV drug resistance
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sequences/sample.
The release of laboratory-scale and affordable next-generation
sequencers like the Roche/454 GS Junior also improves access to
this technology in resource-limited settings where drug resistance
surveillance is most necessary. This benchtop sequencer can allow
in-country genotyping to reduce cost and has the advantage that
fewer samples are required to fill a run than a full size machine
(384 samples). This allows more frequent genotyping and may be
able to accommodate clinical genotyping once validations and
quality control mechanisms are in place. Though our use of the
Roche/454 GS Junior may be higher than could be expected in a
resource-limited setting, in 2011 we ran 250 sequencing runs in a
mid-sized academic research laboratory. Thus, even on this
benchtop sequencer, many samples can be accommodated and
given the WHO recommendation of sequencing at least 47
samples for transmitted drug resistance surveillance in a given
region, one GS Junior may be sufficient for an entire country or
even a region spanning multiple countries [18]. On the other
hand, in places like South Africa where thousands of individuals
may require drug resistance testing for surveillance or clinical care,
this method could easily be scaled-up using the full-sized Roche/
454 Titanium FLX system along with robot-based vRNA
isolations and PCR amplification set-up to accommodate an
estimated 384 patient samples/run. Lastly, since very little starting
material is required for pyrosequencing, it may be possible to take
leftover viral RNA samples from viral load assays and RT-PCR
amplify those products for pyrosequencing. In fact, one study was
recently published showing that dried blood spots could be used
for drug resistance genotyping of 48 patients samples pooled
together by Roche/454 GS FLX sequencing [17].
We emphasize the simplicity of the data analysis pipeline used to
find drug resistance mutations from our pyrosequencing data. We
analyzed sequences using a custom viral sequencing analysis
pipeline that allows simple upload of the .sff file generated at the
end of the sequence run, selection of the optimal parameters
(aligner to use, quality scores to use. etc.) through a graphical user
interface, and generation of a drug resistance table at the end of
the pipeline that can be integrated into a database. The drug
resistance table shows all drug resistance amino acid mutations,
their frequency, number of sequences representing that site and
number of poor sequences that were masked during the pipeline.
The analysis process for a pool of 48 patient samples was
completed in approximately 1 hour. In addition, reports are
generated for each sample where all SNPs and/or amino acid
mutations can be interrogated (not just drug resistance data),
visualized, and exported for further analysis. One advantage of this
sequencing pipeline is the ability to call SNPs in phase. This means
that when two nucleotides within a codon in the same sequence
read are changed, that information is stored and translated
together correctly. Most other analysis pipelines we tested
interrogate all SNPs without considering phase and assume the
other two nucleotides match the reference sequence when
translating the SNP into an amino acid, which can result in
incorrect translations. This data analysis pipeline is available as a
module for LabKey Server, an open-source platform for the
management of scientific data.
There have been several publications describing the use of next-
generation sequencing to study extremely minor drug resistance
mutations in an ultra-deep manner in single individuals [19–21].
However, while there has been two previously published
manuscripts describing the use of pyrosequencing on pooled
samples for HIV drug resistance genotyping, this is the first work
to show the utility of this method on de novo plasma samples that
can be distinguished between each other through MID tags and
covers all known protease and reverse transcriptase drug resistance
mutations [17,22]. In addition, we describe and provide a
simplified and open-source sequence analysis pipeline that allows
accurate detection of mutations found at frequencies at least as
small as 5%. Lastly, utilization of the lab-scaled Roche/454 GS
Junior over the full size Roche/454 GS FLX has the added
advantage of lower cost implementation in limited resource
settings (6-fold cheaper) as well as reduced costs per sample (3-
fold cheaper). Sequencing technology is improving at rapid speed,
however the Roche/454 GS Junior titanium chemistry yields the
most reliable and longest read lengths at this time (,450 bp) on a
benchtop machine. These longer reads allow possible linkage
between mutations found within each of the three amplicons that
may be important when interpreting drug resistance data. An
additional advantage of the method described here over that
previously describing sequencing of pools derived from dried
blood spots, is the use of bidirectional sequence coverage through
tagging both the forward and reverse primer. Bidirectional
sequence coverage improves overall sequence depth of coverage
per sample without adding per-run cost, which improves the
accuracy of lower frequency mutations. As sequencing technology
continues to advance, other lower-cost sequencing platforms like
the Illumina MiSeq (read lengths at 150 bp), which do not have
the same problems with homopolymer sites as pyrosequencing,
may become more cost effective and easier to use.
An important consideration when using pyrosequencing tech-
niques to assess HIV drug resistance is that there are 17 known
drug resistance mutations in the protease and reverse transcriptase
genes located either within or adjacent to homopolymer regions in
the HXB2 backbone (Table 4). This is because homopolymers can
result in stalling of reverse transcriptase, which make mutations in
these areas more likely during HIV replication or during in vitro
cDNA synthesis [23]. As mentioned earlier, homopolymer
sequence regions present an inherent problem with pyrosequenc-
ing, which can result in false insertions or deletions at these sites.
To address SNPs that may be present in these homopolymer
regions we limited our analysis to only those sequences with high
quality scores (.25) at positions reporting an insertion or deletion
relative to the reference in order to minimize false nucleotide base
calls due to homopolymers. While our control sequencing of a
subtype B HXB2 virus indicates that false calls due to homopol-
ymer regions in a subtype B backbone do not impact known drug
resistance sites to a significant level (,0.71%), the same may not
be true in the backbone of other subtypes. Therefore, each HIV
subtype will require validation of the impact of homopolymer sites
on drug resistance mutations identification. For example, one of
the mutations present in a homopolymer region is K65R in the
reverse transcriptase gene. The mutation that is required to
change lysine into arginine occurs two nucleotides from the end of
a homopolymer and would likely disrupt the homopolymer
sufficiently to result in few miscalls, similarly to what is also found
with the K103N mutation. However, in subtype C viruses, the
genetic background is different in the K65R region of pol and the
mutation that is required to result in an arginine change is located
at the end of a homopolymer region [21]. This results in more
potential miscalls through pyrosequencing as well as increased
abundance of this mutation due to stalling of the reverse
transcriptase at that site during HIV replication [24]. These sites
will require further analysis to help automate interpretations of
mutations identified in these regions using pyrosequencing
technology. Limiting sequence analysis to only high quality
sequences and reporting only mutations with frequencies above
our error threshold (0.71%) can help prevent falsely identifying
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homopolymer regions.
We chose to focus our efforts on mutations present in at least
5% of the virus population. This threshold was chosen primarily to
be well above our error threshold, however, there is also
conflicting evidence about whether mutations influence drug
failure when they are present at levels below 5%, or even the 20%
detection limit of current drug resistance genotyping methods
[20,21,25–30]. Therefore we did not focus our efforts on
mutations present at very low frequencies, which require
additional considerations with 454 pyrosequencing data. Most of
the mutations identified in this study were present at high
frequencies nearing 100%. However, we detected mutations with
frequencies as small as 4.7% (when limiting analysis to those at 5%
or above when rounding), which would have been missed with the
current HIV drug resistance genotyping method that has an
accepted limit of detection at a frequency of 20%. Despite the
controversy, there is some evidence that detection of mutations at
frequencies below the current genotyping method limit of
detection may be beneficial in HIV drug resistance surveillance
efforts for early detection of transmitted drug resistance [31].
Overall, we detected 7 mutations with frequencies under 20% that
would theoretically be missed by traditional Sanger-based
genotyping methods, 4 of which occurred in 3 patients failing
treatment (Table 3).
Overall, our approach produces high quality sequence data that
is more sensitive and less expensive than the currently available
HIV drug resistance genotyping methods. We are currently
seeking ways to improve the percentages of successful amplifica-
tion and sequencing using this method. Until these improvements
have been made, this method would likely be best utilized for drug
resistance surveillance efforts. We believe this approach can be
optimized to accurately genotype HIV from different subtypes and
can be scaled up to accommodate extensive efforts for drug
resistance surveillance currently proposed in many low and
middle-income countries. Lastly, with proper validations, this
method could improve accessibility of HIV drug resistance
genotyping to patients in low-income settings to improve clinical
care and success of antiretroviral therapy.
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